Clinical Trial Detail

NCT ID NCT04216316
Title Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Avelumab + Carboplatin + Gemcitabine

Avelumab + Berzosertib + Carboplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.